Who makes NS-136 tablet?

NS-136 tablet is developed by NeuShen Therapeutics.

Last reviewed 2026-04-19 · How we verify

NS-136 tablet

NeuShen Therapeutics · Phase 1 active Small molecule

At a glance

Generic name	NS-136 tablet
Sponsor	NeuShen Therapeutics
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First-into-human Study of NS-136 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NS-136 tablet CI brief — competitive landscape report
NS-136 tablet updates RSS · CI watch RSS
NeuShen Therapeutics portfolio CI